Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial

Lancet

Volumn 354, Issue 9194, 1999, Pages 1932-1939

  Maini, Ravinder ^a   St Clair, E William ^b   Breedveld, Ferdinand ^c   Furst, Daniel ^d   Kalden, Joachim ^e   Weisman, Michael ^f   Smolen, Josef ^j   Emery, Paul ^g   Harriman, Gregory ^h   Feldmann, Marc ^a   Lipsky, Peter ⁱ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DUKE UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h CENTOCOR INC   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RHINITIS; SINUSITIS; STOMATITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO;

EID: 0033524159     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)05246-0     Document Type: Article

References (23)

1. Weinblatt M.E., Kaplan H., Germain B.F.et al. Methotrexate in rheumatoid arthritis: a five year prospective study. Arthritis Rheum. 37:1994;1492-1498.
2. Maetzel A., Bombardier C., Strand V.et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol. 25:1998;2331-2338.
3. Tugwell P., Pincus T., Yocum D.et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 333:1995;137-141.
4. O'Dell J.R., Haire C.E., Erikson N.et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 334:1996;1287-1291.
5. Wolfe F., Hawley D.J., Cathey M.A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 17:1990;994-1002.
6. Maini R.N., Elliott M.J., Brennan F.M.et al. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 144:1995;195-223.
7. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol. 14:1996;397-440.
8. Knight D.M., Trinh H., Le J.et al. Construction and initial characterisation of a mouse-human chimaeric anti-TNF antibody. Mol Immunol. 30:1993;1443-1453.
9. Elliott M.J., Maini R.N., Feldmann M.et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
10. Elliott M.J., Maini R.N., Feldmann M.et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
11. Elliott M.J., Maini R.N., Feldmann M.et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
12. Rankin E.C.C., Choy E.H.S., Kassimos D.et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheum. 34:1995;334-342.
13. Moreland L.W., Baumgartner S.W., Schiff M.H.et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 337:1997;141-147.
14. Moreland L.W., Schiff M.H., Baumgartner S.W.et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med. 130:1999;478-486.
15. Maini R.N., Breedveld F.C., Kalden J.R.et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563.
16. Weinblatt M.E., Kremer J.M., Bankhust A.D.et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:1999;253-259.
17. Hochberg M.C., Chang R.W., Dwosh I.et al. The American College of Rheumatology revised criteria for the classification of global function status in rheumatoid arthritis. Arthritis Rheum 1992. 35:1991;498-502.
18. Felson D.T., Anderson J.J., Boers M.et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:1995;727-735.
19. Fries J.F., Spitz P.W., Young D.Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 9:1982;789-793.
20. Surveillance, Epidemiology and End Results [SEER] Program Public Use CD-ROM (1973-1995), National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch, released April 1998, based on August 1997 submission.
21. Williams C.A., Bloch D.A., Sibley J.et al. Lymphoma and leukemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate? J Clin Rheum. 2:1996;64-72.
22. Jones M., Symmons D., Finn J., Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheum. 35:1996;738-745.
23. Baecklund E., Ekbom A., Sparen P.et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: a nested case-control study. BMJ. 317:1998;180-181.